Glembatumumab - CISMeF

Preferred Label : Glembatumumab;

NCIt synonyms : Immunoglobulin, Anti-(Human Glycoprotein NMB Extracellular Domain) (Human Monoclonal CR011 Heavy Chain), Disulfide with Human Monoclonal CR011 Gamma-2 Kappa-Chain, Dimer; Immunoglobulin G2, Anti-(Human Transmembrane Glycoprotein NMB (HGFIN) Extracellular Domain) Human Monoclonal CR011 Heavy Chain (133-215')-Disulfide with Human Monoclonal CR011 Kappa Light Chain, Dimer (221-221'':222-222'':225-225'':228- 228'')-Tetrakis;

NCIt definition : A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer cells, but alone does not appear to inhibit cancer cell growth. However, this antibody could be utilized to deliver a conjugated cytotoxic agent to GPNMB-expressing tumor cells. GPNMB, overexpressed on the surface of various cancer cells, plays a key role in cancer cell proliferation.;

UNII : WEC7MEM1BR;

CAS number : 1020264-78-1;

Molecule name : CR011;

Details

Origin ID

C84520;

UMLS CUI

C2827489;

Currated CISMeF NLP mapping
- Glembatumumab [SMS substance]
See also inter- (CISMeF)
- GPNMB protein, human [MeSH Supplementary Concept]
Semantic type(s)
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- OS Authorized Value Terminology [NCIt concept]
- OS Total Dose Table [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients